International nosocomial infection control consortium (INICC) report, data summary of 36 countries, for 2004-2009

The results of a surveillance study conducted by the International Nosocomial Infection Control Consortium (INICC) from January 2004 through December 2009 in 422 intensive care units (ICUs) of 36 countries in Latin America, Asia, Africa, and Europe are reported. During the 6-year study period, using Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN; formerly the National Nosocomial Infection Surveillance system [NNIS]) definitions for device-associated health care-associated infections, we gathered prospective data from 313,008 patients hospitalized in the consortium's ICUs for an aggregate of 2,194,897 ICU bed-days. Despite the fact that the use of devices in the developing countries' ICUs was remarkably similar to that reported in US ICUs in the CDC's NHSN, rates of device-associated nosocomial infection were significantly higher in the ICUs of the INICC hospitals; the pooled rate of central line-associated bloodstream infection in the INICC ICUs of 6.8 per 1,000 central line-days was more than 3-fold higher than the 2.0 per 1,000 central line-days reported in comparable US ICUs. The overall rate of ventilator-associated pneumonia also was far higher (15.8 vs 3.3 per 1,000 ventilator-days), as was the rate of catheter-associated urinary tract infection (6.3 vs. 3.3 per 1,000 catheter-days). Notably, the frequencies of resistance of Pseudomonas aeruginosa isolates to imipenem (47.2% vs 23.0%), Klebsiella pneumoniae isolates to ceftazidime (76.3% vs 27.1%), Escherichia coli isolates to ceftazidime (66.7% vs 8.1%), Staphylococcus aureus isolates to methicillin (84.4% vs 56.8%), were also higher in the consortium's ICUs, and the crude unadjusted excess mortalities of device-related infections ranged from 7.3% (for catheter-associated urinary tract infection) to 15.2% (for ventilator-associated pneumonia). Copyright © 2012 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved

Germination of phaseolus vulgaris and alcalase hydrolysis of its proteins produced bioactive peptides capable of improving markers related to type-2 diabetes in vitro

The aim of this study was to evaluate the effect of germination and alcalase hydrolysis of common bean proteins on the generation of bioactive peptides with potential to reduce parameters related to the risk of developing type-2 diabetes (T2D) in vitro. Germination (25 °C up to 72 h) and alcalase hydrolysis (up to 4 h) produced peptides with high antioxidant capacity (1085 μmol TE/g soluble protein, SP). After 24 h of germination, there was an increase of 44% in α-amylase inhibitory capacity of the peptides relative to acarbose (1 mM). Simulated gastrointestinal digestion of the non-germinated and non-hydrolyzed sample (G0-0h) produced bioactive peptides that inhibited dipeptidyl peptidase-IV (DPP-IV) (IC50 = 1.2 mg SP/mL); however, the IC50 was not improved by either germination or alcalase hydrolysis. Insulin secretion by glucose stimulated (20 mM) INS-1E pancreatic β-cells, increased 45% from the basal state with 2 mg SP/mL of G0-0h. Germination did not improve the stimulation of insulin. Computational modeling showed that the peptide RGPLVNPDPKPFL obtained after 48 h germination and 1 h alcalase-hydrolysis was able to inhibit DPP-IV by interacting with its S1, S2, and S3 pockets of the active site. Germination and alcalase hydrolysis can be applied to improve some markers related to the management of T2D. Furthermore, simulated gastrointestinal digestion of common bean proteins without any treatment produced bioactive peptides with the ability to inhibit DPP-IV, resulting in increased insulin released from pancreatic cells in vitro.76150159FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP2012/19034-